Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials

Revolution Medicines, Inc.

2023-FY EPS reported -$3.86 revenue$11,580,000

Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.
Revenue fell to $0.7M (Q4) and $11.6M (FY) due to Sanofi collaboration termination in 2023.
Cash, equivalents and securities $1.85B as of Dec 31, 2023, up from $644.9M a year ago (EQRx acquisition and equity offering).
Plans to start pivotal Phase 3 trials for RMC-6236 in 2L NSCLC and 2L PDAC in H2 2024.
2024 GAAP net loss guidance $480M-$520M; cash runway into 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-020125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.